NewLimit is developing epigenetic therapies to extend human healthspan by reprogramming aging cells.
About
NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines. They leverage advanced genomics, machine learning, and cellular biology to identify and manipulate epigenetic drivers of aging, aiming to restore youthful function in aged cells and treat age-related diseases. Their approach involves a "lab in a loop" system where AI models predict and experiments validate therapeutic candidates.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does NewLimit do?
NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines. They leverage advanced genomics, machine learning, and cellular biology to identify and manipulate epigenetic drivers of aging, aiming to restore youthful function in aged cells and treat age-related diseases. Their approach involves a "lab in a loop" system where AI models predict and experiments validate therapeutic candidates.
How much funding has NewLimit raised?
NewLimit has raised a total of $215M in funding. The most recent round on record is Series B Extension.
Where is NewLimit headquartered?
NewLimit is headquartered in San Francisco Bay Area, USA.
When was NewLimit founded?
NewLimit was founded in 2022.
What industry does NewLimit operate in?
NewLimit operates in Biotech, Longevity, Epigenetics, Drug Discovery, Machine Learning, Genomics.